{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:34:39Z","timestamp":1778538879032,"version":"3.51.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 CA 137443"],"award-info":[{"award-number":["UM1 CA 137443"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Adult Brain Tumor Consortium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The blood-brain barrier (BBB) severely limits the delivery of therapeutic agents to the brain. Regadenoson, a Food and Drug Administration-approved adenosine A2 agonist, transiently increases BBB permeability in rodents to a 70\u00a0kDa dextran. This multi-institutional, NIH-funded study examined regadenoson\u2019s ability to transiently alter BBB permeability in patients with gliomas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults with supratentorial gliomas at low risk for regadenoson complications were treated with 1 of the 7 dose levels known to be safe in humans. Successful BBB disruption was defined as a 10-fold increase in vascular permeability (Ktrans) relative to historic benchmarks. This was assessed by dynamic contrast-enhanced perfusion on magnetic resonance imaging in normal-appearing white matter (NAWM) changes in NAWM and non-enhancing tumors were also quantified using contrast-enhanced T1 subtraction maps.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven patients &amp;lt;45 years old with low-grade gliomas were accrued before the study was prematurely closed. Regadenoson was well tolerated. Following regadenoson, Ktrans in NAWM did not reach the targeted Ktrans threshold (0.04\u00a0min\u22121). Normalized subtraction maps of contrast-enhanced T1-weighted MR signal intensity in NAWM did increase an average of 74% \u00b1 22% (P\u2005=\u2005.016) after regadenoson.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No dose of regadenoson significantly elevated Ktrans in NAWM. However, the subtraction maps suggest that regadenoson may lead to a measurable change in gadolinium flux. This coupled with strong preclinical data suggests further investigation is warranted. Noninvasive quantification of BBB permeability in patients is feasible and could evaluate different regadenoson schedules, combination therapies, and other approaches to modify BBB permeability which is critical to improving outcomes in patients with brain tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>NCI Protocol #: Adult brain tumor consortium 1804, ClinicalTrials.gov Identifier: NCT03971734, Agent(s): Regadenoson, NSC # 811401, commercially available.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf041","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:43:56Z","timestamp":1739627036000},"source":"Crossref","is-referenced-by-count":2,"title":["Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3726-7679","authenticated-orcid":false,"given":"Stuart A","family":"Grossman","sequence":"first","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-7047","authenticated-orcid":false,"given":"Carlos G","family":"Romo","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kral","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy E","family":"Strowd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, Wake Forest University School of Medicine , Wake Forest, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Lesser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, Wake Forest University School of Medicine , Wake Forest, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-439X","authenticated-orcid":false,"given":"Catalina","family":"Raymond","sequence":"additional","affiliation":[{"name":"UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers , Los Angeles, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaella","family":"Iacoboni","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Desideri","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraja","family":"Danda","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M","family":"Ellingson","sequence":"additional","affiliation":[{"name":"UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers , Los Angeles, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"2025041211213702400_CIT0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014","volume":"19","author":"Ostrom","year":"2017","journal-title":"Neuro Oncol"},{"issue":"5","key":"2025041211213702400_CIT0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med."},{"issue":"22","key":"2025041211213702400_CIT0003","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.3390\/ijms222212111","article-title":"Form and function of the vertebrate and invertebrate blood-brain barriers","volume":"22","author":"Dunton","year":"2021","journal-title":"Int J Mol Sci ."},{"issue":"7","key":"2025041211213702400_CIT0004","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2174\/1570159X20999220131163504","article-title":"Transient opening of the blood-brain barrier by vasoactive peptides to increase CNS drug delivery: Reality versus wishful thinking","volume":"20","author":"Smith-Cohn","year":"2022","journal-title":"Curr Neuropharmacol."},{"issue":"1","key":"2025041211213702400_CIT0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"issue":"11","key":"2025041211213702400_CIT0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11940-019-0598-6","article-title":"Brain metastases as a first site of recurrence in patients receiving chemotherapy with controlled systemic cancer: A Critical but Under-Recognized Clinical Scenario","volume":"21","author":"O\u2019Connell","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"11","key":"2025041211213702400_CIT0007","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.25707","article-title":"Presentation, patterns of care, and survival in patients with brain metastases: What has changed in the last 20 years","volume":"117","author":"Nieder","year":"2011","journal-title":"Cancer."},{"issue":"5","key":"2025041211213702400_CIT0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","article-title":"Strategies to improve drug delivery across the blood-brain barrier for glioblastoma","volume":"24","author":"Narsinh","year":"2024","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"2","key":"2025041211213702400_CIT0009","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006123-199902000-00015","article-title":"Intra-arterial Cereport (RMP-7) and carboplatin: A dose escalation study for recurrent malignant gliomas","volume":"44","author":"Cloughesy","year":"1999","journal-title":"Neurosurgery."},{"issue":"6","key":"2025041211213702400_CIT0010","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol."},{"issue":"2","key":"2025041211213702400_CIT0011","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11060-020-03435-6","article-title":"Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: Where are we now, and where we are going","volume":"147","author":"D\u2019Amico","year":"2020","journal-title":"J Neurooncol."},{"issue":"11","key":"2025041211213702400_CIT0012","first-page":"953","article-title":"Optimizing the delivery of antineoplastic therapies to the central nervous system","volume":"30","author":"Naidoo","year":"2016","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"2025041211213702400_CIT0013","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0361-9230(03)00043-1","article-title":"Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: Laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport","volume":"60","author":"Borlongan","year":"2003","journal-title":"Brain Res Bull."},{"issue":"1\u20133","key":"2025041211213702400_CIT0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0162-3109(96)00070-7","article-title":"Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: Evidence for a sensitive, auto-regulated, receptor-mediated system","volume":"33","author":"Bartus","year":"1996","journal-title":"Immunopharmacology."},{"issue":"3","key":"2025041211213702400_CIT0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-005-0172-7","article-title":"Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: A report from the Children\u2019s Oncology Group","volume":"58","author":"Warren","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"issue":"37","key":"2025041211213702400_CIT0016","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.1523\/JNEUROSCI.3337-11.2011","article-title":"Adenosine receptor signaling modulates permeability of the blood-brain barrier","volume":"31","author":"Carman","year":"2011","journal-title":"J Neurosci."},{"key":"2025041211213702400_CIT0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12987-015-0017-7","article-title":"Adenosine receptor signaling: A key to opening the blood-brain door","volume":"12","author":"Bynoe","year":"2015","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"2025041211213702400_CIT0018","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12035-014-8879-2","article-title":"A2A adenosine receptor regulates the human blood-brain barrier permeability","volume":"52","author":"Kim","year":"2015","journal-title":"Mol Neurobiol."},{"issue":"5","key":"2025041211213702400_CIT0019","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI76207","article-title":"A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier","volume":"126","author":"Kim","year":"2016","journal-title":"J Clin Invest."},{"issue":"6","key":"2025041211213702400_CIT0020","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/15257770802145678","article-title":"Regulation of leukocyte migration across endothelial barriers by ECTO-5\u2019-nucleotidase-generated adenosine","volume":"27","author":"Thompson","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids."},{"key":"2025041211213702400_CIT0021","volume-title":"Lexiscan (regadenoson) [package insert]","year":"2018"},{"issue":"3","key":"2025041211213702400_CIT0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11060-015-1998-4","article-title":"The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain","volume":"126","author":"Jackson","year":"2016","journal-title":"J Neurooncol."},{"issue":"3","key":"2025041211213702400_CIT0023","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11060-017-2404-1","article-title":"The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study","volume":"132","author":"Jackson","year":"2017","journal-title":"J Neurooncol."},{"issue":"1","key":"2025041211213702400_CIT0024","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12987-017-0088-8","article-title":"The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma","volume":"15","author":"Jackson","year":"2018","journal-title":"Fluids Barriers CNS"},{"issue":"12","key":"2025041211213702400_CIT0025","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2165\/00003088-200645120-00005","article-title":"A population pharmacokinetic\/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers","volume":"45","author":"Gordi","year":"2006","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"2025041211213702400_CIT0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12350-015-0327-9","article-title":"Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study","volume":"24","author":"Townsend","year":"2017","journal-title":"J Nucl Cardiol."},{"issue":"11","key":"2025041211213702400_CIT0027","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2005.05.097","article-title":"Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging","volume":"46","author":"Hendel","year":"2005","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"2025041211213702400_CIT0028","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols","volume":"10","author":"Tofts","year":"1999","journal-title":"J Magn Reson Imaging."},{"issue":"2","key":"2025041211213702400_CIT0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mrm.1910170208","article-title":"Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts","volume":"17","author":"Tofts","year":"1991","journal-title":"Magn Reson Med."},{"issue":"5","key":"2025041211213702400_CIT0030","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jmri.20182","article-title":"Comparative study of methods for determining vascular permeability and blood volume in human gliomas","volume":"20","author":"Harrer","year":"2004","journal-title":"J Magn Reson Imaging."},{"issue":"20","key":"2025041211213702400_CIT0031","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-15-2529","article-title":"ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI","volume":"22","author":"Gerstner","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2025041211213702400_CIT0032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/noy018","article-title":"Understanding brain penetrance of anticancer drugs","volume":"20","author":"Levin","year":"2018","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025041211213702400_CIT0033","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/radiol.13131305","article-title":"Recurrent glioblastoma treated with bevacizumab: Contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial","volume":"271","author":"Ellingson","year":"2014","journal-title":"Radiology."},{"issue":"5","key":"2025041211213702400_CIT0034","first-page":"891","article-title":"Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade","volume":"21","author":"Roberts","year":"2000","journal-title":"AJNR Am J Neuroradiol."},{"issue":"1","key":"2025041211213702400_CIT0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/neuonc\/now187","article-title":"Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: Evidence from single and multicenter trials","volume":"19","author":"Ellingson","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025041211213702400_CIT0036","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jmri.23675","article-title":"Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas","volume":"36","author":"Zhang","year":"2012","journal-title":"J Magn Reson Imaging."},{"key":"2025041211213702400_CIT0037","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jocn.2011.08.030","article-title":"Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging","volume":"19","author":"Jia","year":"2012","journal-title":"J Clin Neurosci."},{"key":"2025041211213702400_CIT0038","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jocn.2012.09.019","article-title":"Low-grade and anaplastic oligodendrogliomas: differences in tumour microvascular permeability evaluated with dynamic contrast-enhanced magnetic resonance imaging","volume":"20","author":"Jia","year":"2013","journal-title":"J Clin Neurosci."},{"issue":"10","key":"2025041211213702400_CIT0039","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/neuonc\/noy054","article-title":"Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma","volume":"20","author":"Ellingson","year":"2018","journal-title":"Neuro Oncol"},{"key":"2025041211213702400_CIT0040","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-27359-0_4","article-title":"Contrast-enhanced T1-weighted digital subtraction for increased lesion conspicuity and quantifying treatment response in malignant gliomas","volume-title":"Glioma imaging","author":"Ellingson","year":"2020"},{"issue":"2","key":"2025041211213702400_CIT0041","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"10","key":"2025041211213702400_CIT0042","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ng.2734","article-title":"The integrated landscape of driver genomic alterations in glioblastoma","volume":"45","author":"Frattini","year":"2013","journal-title":"Nat Genet."},{"issue":"22","key":"2025041211213702400_CIT0043","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1021\/acs.jmedchem.6b00618","article-title":"Small molecule kinase inhibitors for the treatment of brain cancer","volume":"59","author":"Heffron","year":"2016","journal-title":"J Med Chem."},{"key":"2025041211213702400_CIT0044","doi-asserted-by":"crossref","first-page":"101896","DOI":"10.1016\/j.ctrv.2019.101896","article-title":"Molecular targeted therapy of glioblastoma","volume":"80","author":"Le Rhun","year":"2019","journal-title":"Cancer Treat Rev."},{"issue":"11","key":"2025041211213702400_CIT0045","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin Cancer Res."},{"key":"2025041211213702400_CIT0046","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11682-018-9855-7","article-title":"Blood\u2013brain barrier leakage in relation to white matter hyperintensity volume and cognition in","volume":"13","author":"Zhang","year":"2019","journal-title":"Brain Imaging and Behavior"},{"issue":"10","key":"2025041211213702400_CIT0047","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/jcbfm.2014.126","article-title":"Accurate determination of blood-brain barrier permeability using dynamic contrast-enhanced T1-weighted MRI: A simulation and in vivo study on healthy subjects and multiple sclerosis patients","volume":"34","author":"Cramer","year":"2014","journal-title":"J Cereb Blood Flow Metab."},{"issue":"5","key":"2025041211213702400_CIT0048","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/mrm.25793","article-title":"Optimal acquisition and modeling parameters for accurate assessment of low Ktrans blood-brain barrier permeability using dynamic contrast-enhanced MRI","volume":"75","author":"Barnes","year":"2016","journal-title":"Magn Reson Med."},{"key":"2025041211213702400_CIT0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1162\/imag_a_00324","article-title":"Measurement variability of blood\u2013brain barrier permeability using dynamic contrast-enhanced magnetic resonance imaging","volume":"2","author":"Varatharaj","year":"2024","journal-title":"Imaging Neuroscience"},{"issue":"1","key":"2025041211213702400_CIT0050","first-page":"vdab174","article-title":"Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma","volume":"3","author":"Woodall","year":"2021","journal-title":"Neurooncol. Adv.."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf041\/61902993\/vdaf041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf041\/61902993\/vdaf041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdaf041\/61902993\/vdaf041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:21:53Z","timestamp":1744456913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf041\/8016070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf041","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]},"article-number":"vdaf041"}}